Cytokinetics INC Schedule 13G passive stakes

FMR LLC, through its subsidiaries and affiliates, has disclosed beneficial ownership of 5,248,579.71 shares, representing 3.9% of the outstanding common stock of Cytokinetics Inc., as of June 30, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 9.0% of Cytokinetics Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.21% beneficial ownership stake in Cytokinetics Inc.

The Vanguard Group has reported a 0% beneficial ownership in Cytokinetics Inc. following an internal realignment.

T. Rowe Price Investment Management, Inc. reported an amended beneficial ownership of 16.0% in Cytokinetics Inc., holding 19,097,373 common shares.

State Street Corporation has filed a Schedule 13G, reporting a 4.7% beneficial ownership stake in Cytokinetics Inc. common stock as of September 30, 2025.

T. Rowe Price Investment Management, Inc. has reported an increased beneficial ownership of 14.7% in Cytokinetics Inc., holding 17,602,440 shares.

FMR LLC and Abigail P. Johnson have reported an aggregate beneficial ownership of 10.9% of Cytokinetics Inc.'s common stock as of July 31, 2025.

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 11.3% in Cytokinetics Inc., totaling 13,420,144 shares of common stock, as a passive investment.

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a beneficial ownership of 9.4% of Cytokinetics Inc.'s common stock as of December 31, 2024.

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.09% beneficial ownership stake in Cytokinetics Inc as of December 31, 2024.